Peter Ljubenkov, MD
Enriched profileAssociate Professor of Neurology · University of California, San Francisco
Peter Ljubenkov is Associate Professor of Neurology at University of California, San Francisco. OpenAlex indexes 92 publications with 1,873 citations (h-index 26); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 18 Oct 2026
Peter Ljubenkov, M.D., is Associate Professor of Neurology at University of California, San Francisco (Memory and Aging Center). The public record shows 92 publications with 1,873 citations (h-index 26), centered on Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Amyotrophic Lateral Sclerosis Research. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 1 companies, 1 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Neurocase
- Top research focus: Dementia and Cognitive Impairment Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 37.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Alzheimer's Tau Platform: Master Protocol
Sponsor: Paul S. Aisen
- Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Sponsor: Peter Ljubenkov, MD
- Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
Sponsor: Woolsey Pharmaceuticals
Industry payments
Updated 18 Oct 2026
1 company reported payments to CMS in program years 2022–2022. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year20221 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Cholinesterase Inhibitor45.2%Donepezil Hcl64%Rivastigmine36%Part D<11 patientsSSRI28.9%Escitalopram Oxalate58%Trazodone Hcl42%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2021–2026 per NIH RePORTER. The latest:
- Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
University of California, San Francisco
FY2026$688,110R01AG073482 - Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
University of California, San Francisco
FY2024$633,691R01AG073482 - Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
University of California, San Francisco
FY2023$638,870R01AG073482
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer Disease.
Neurology. Clinical practice
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Lewis Katz School of Medicine at Temple University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →memory.ucsf.edu ↗
Editorial & leadership roles
journal and society appointments- Director
UCSF Alzheimer's Infusion Core
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →memory.ucsf.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health